Fadlo R Khuri

List of Publications by Citations

Source: https://exaly.com/author-pdf/6529612/fadlo-r-khuri-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

488 papers	43,766 citations	101 h-index	196 g-index
629 ext. papers	54,488 ext. citations	9 avg, IF	6.71 L-index

#	Paper	IF	Citations
488	Genomic Classification of Cutaneous Melanoma. *Cell*, **2015**, 161, 1681-96	56.2	1807
487	The Immune Landscape of Cancer. *Immunity*, **2018**, 48, 812-830.e14	32.3	1754
486	Integrated genomic characterization of papillary thyroid carcinoma. *Cell*, **2014**, 159, 676-90	56.2	1660
485	Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*, **2018**, 173, 321-337.e10	56.2	1124
484	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, **2018**, 173, 400-416.e11	56.2	1072
483	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1998-2006	27.4	1042
482	Integrated genomic characterization of oesophageal carcinoma. *Nature*, **2017**, 541, 169-175	50.4	965
481	a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nature Medicine*, **2000**, 6, 879-85	50.5	928
480	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*, **2018**, 173, 291-304.e6	56.2	888
479	Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*, **2018**, 173, 371-385.e18	56.2	854
478	Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. *Cancer Research*, **2005**, 65, 7052-8	10.1	702
477	The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discovery*, **2011**, 1, 44-53	24.4	660
476	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell*, **2018**, 173, 338-354.e15	56.2	560
475	Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. *Science Signaling*, **2009**, 2, ra73	8.8	520
474	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. *Lancet Oncology, The*, **2013**, 14, 257-64	21.7	473
473	Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. *Journal of the National Cancer Institute*, **1999**, 91, 763-71	9.7	432
472	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Reports*, **2018**, 23, 239-254.e6	10.6	405

471	Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. *Journal of Clinical Oncology*, **2001**, 19, 289-98	2.2	400
470	Perspectives for cancer prevention with natural compounds. *Journal of Clinical Oncology*, **2009**, 27, 2712-25	2.2	395
469	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*, **2018**, 33, 676-689.e3	24.3	377
468	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4993-4998	11.5	375
467	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Reports*, **2018**, 23, 181-193.e7	10.6	366
466	Cancer prevention with natural compounds. *Seminars in Oncology*, **2010**, 37, 258-81	5.5	350
465	Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*, **2018**, 173, 355-370.e14	56.2	342
464	Clonal genetic alterations in the lungs of current and former smokers. *Journal of the National Cancer Institute*, **1997**, 89, 857-62	9.7	342
463	Lung cancer: New biological insights and recent therapeutic advances. *Ca-A Cancer Journal for Clinicians*, **2011**, 61, 91-112	220.7	329
462	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell*, **2018**, 34, 211-224.e6	24.3	327
461	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Systems*, **2018**, 6, 271-281.e7	10.6	320
460	Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. *Journal of Clinical Oncology*, **2000**, 18, 609-22	2.2	297
459	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports*, **2018**, 23, 313-326.e5	10.6	295
458	Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. *Cancer Research*, **2011**, 71, 1526-32	10.1	292
457	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. *Clinical Cancer Research*, **2002**, 8, 1178-84	12.9	278
456	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*, **2018** , 33, 690-705.e9	24.3	277
455	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*, **2018**, 33, 706-720.e9	24.3	275
454	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Journal of the National Cancer Institute*, **2005**, 97, 94-102	9.7	275

453	Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. *Cancer Cell*, **2012**, 22, 585-600	24.3	268
452	Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. *Journal of the National Cancer Institute*, **2001**, 93, 605-18	9.7	267
451	Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. *Lung Cancer*, **2004**, 44, 369-79	5.9	237
450	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. *Cell Reports*, **2018**, 23, 227-238.e3	10.6	235
449	Targeting protein-protein interactions as an anticancer strategy. *Trends in Pharmacological Sciences*, **2013**, 34, 393-400	13.2	230
448	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*, **2018**, 33, 721-735.e8	24.3	228
447	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. *Journal of Clinical Oncology*, **2013**, 31, 3320-6	2.2	227
446	Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. *Molecular Cell*, **2011**, 44, 864-77	17.6	224
445	Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. *Journal of the National Cancer Institute*, **2004**, 96, 1769-80	9.7	218
444	Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. *Journal of the National Cancer Institute*, **2000**, 92, 1511-6	9.7	217
443	Phase I trial of oral green tea extract in adult patients with solid tumors. *Journal of Clinical Oncology*, **2001**, 19, 1830-8	2.2	198
442	Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. *Cancer Cell*, **2015**, 27, 257-70	24.3	194
441	Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. *Cancer*, **2012**, 118, 4444-51	6.4	194
440	Epidermal growth factor receptor biology (IMC-C225). *Current Opinion in Oncology*, **2001**, 13, 506-13	4.2	191
439	Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. *Journal of Clinical Oncology*, **2004**, 22, 4384-93	2.2	189
438	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Reports*, **2018**, 23, 282-296.e4	10.6	188
437	Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. *Journal of the National Cancer Institute*, **2006**, 98, 441-50	9.7	188
436	Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. *Molecular Cell*, **2014**, 53, 534-48	17.6	184

435	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. *Cancer*, **2018**, 124, 271-277	6.4	173
434	Mode of action of docetaxel - a basis for combination with novel anticancer agents. *Cancer Treatment Reviews*, **2003**, 29, 407-15	14.4	171
433	Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. *Journal of Clinical Oncology*, **2003**, 21, 1167-73	2.2	168
432	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. *Cell*, **2018**, 173, 305-320.e10	56.2	166
431	Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. *Cancer Research*, **2006**, 66, 315-23	10.1	165
430	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Systems*, **2018**, 6, 282-300.e2	10.6	159
429	Translation of innovative designs into phase I trials. *Journal of Clinical Oncology*, **2007**, 25, 4982-6	2.2	158
428	c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. *Cancer Research*, **2004**, 64, 7570-8	10.1	158
427	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. *Nature Cell Biology*, **2015**, 17, 1484-96	23.4	153
426	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Reports*, **2018**, 25, 1304-1317.e5	10.6	152
425	p53 upregulates death receptor 4 expression through an intronic p53 binding site. *Cancer Research*, **2004**, 64, 5078-83	10.1	148
424	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Reports*, **2018**, 23, 297-312.e12	10.6	147
423	The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. *Cancer Research*, **2007**, 67, 4981-8	10.1	147
422	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Reports*, **2018**, 23, 194-212.e6	10.6	146
421	Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. *Molecular and Cellular Biology*, **2011**, 31, 4938-50	4.8	146
420	Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. *Seminars in Cancer Biology*, **2006**, 16, 193-202	12.7	144
419	Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. *Cancer Research*, **2008**, 68, 7409-18	10.1	140
418	Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. *Molecular Pharmacology*, **2008**, 74, 654-61	4.3	135

417	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*, **2018**, 173, 386-399.e12	56.2	133
416	Use of replicating oncolytic adenoviruses in combination therapy for cancer. *Clinical Cancer Research*, **2004**, 10, 5299-312	12.9	132
415	Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. *Cancer Research*, **2009**, 69, 8967-76	10.1	127
414	Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. *Cancer*, **2013**, 119, 2602-10	6.4	125
413	Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 162-7	11.5	125
412	Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. *Molecular and Cellular Biology*, **2007**, 27, 7405-13	4.8	125
411	Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. *Cancer Research*, **2007**, 67, 6946-55	10.1	123
410	Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. *Journal of Clinical Oncology*, **2004**, 22, 4575-83	2.2	123
409	Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). *Cancer Causes and Control*, **2003**, 14, 131-8	2.8	123
408	14-3-3 proteins as potential therapeutic targets. *Seminars in Cell and Developmental Biology*, **2011**, 22, 705-12	7.5	122
407	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. *Cell Reports*, **2018**, 23, 270-281.e3	10.6	121
406	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. *Molecular Cancer Therapeutics*, **2013**, 12, 2200-12	6.1	115
405	p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. *Journal of Clinical Investigation*, **2010**, 120, 1165-77	15.9	114
404	Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. *Journal of Clinical Oncology*, **2002**, 20, 364-70	2.2	113
403	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Reports*, **2018**, 23, 255-269.e4	10.6	112
402	Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. *Clinical Cancer Research*, **2005**, 11, 6261-9	12.9	112
401	Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. *Thyroid*, **2014**, 24, 232-40	6.2	108
400	A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. *Lung Cancer*, **2001**, 34, 427-32	5.9	108

399	Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. *Oncogene*, **2017**, 36, 3797-3806	9.2	107
398	The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. *Nature Communications*, **2017**, 8, 14356	17.4	107
397	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. *Mayo Clinic Proceedings*, **2015**, 90, 996-1000	6.4	105
396	Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. *Cancer*, **2012**, 118, 4571-8	6.4	105
395	Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. *Journal of Clinical Oncology* , **2001**, 19, 2626-37	2.2	104
394	Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. *Cancer*, **2004**, 101, 2837-42	6.4	101
393	Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. *Journal of Clinical Oncology*, **2001**, 19, 3010-7	2.2	101
392	Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. *Journal of Clinical Oncology*, **1998**, 16, 1325-30	2.2	101
391	Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. *Clinical Cancer Research*, **2002**, 8, 3669-75	12.9	101
390	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. *Cancer*, **2014**, 120, 1145-54	6.4	100
389	Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. *Cancer Research*, **2008**, 68, 7484-92	10.1	100
388	Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. *Journal of Biological Chemistry*, **2004**, 279, 26287-99	5.4	96
387	Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. *Journal of Clinical Oncology*, **2004**, 22, 3230-7	2.2	96
386	The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. *Cancer Research*, **2005**, 65, 3883-93	10.1	93
385	Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. *Journal of the National Cancer Institute*, **1998**, 90, 991-5	9.7	93
384	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. *Molecular Cell*, **2015**, 59, 345-358	17.6	91
383	Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. *Journal of Biological Chemistry*, **2010**, 285, 34557-65	5.4	91
382	Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. *Journal of Clinical Oncology*, **2002**, 20, 1593-9	2.2	89

381	Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. *Journal of Clinical Oncology*, **2002**, 20, 4440-7	2.2	89
380	A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 866-72	8.9	88
379	The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. *Journal of Biological Chemistry*, **2009**, 284, 23225-33	5.4	88
378	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. *Cancer Cell*, **2015**, 27, 852-63	24.3	86
377	Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. *Cancer Biology and Therapy*, **2009**, 8, 1463-9	4.6	86
376	Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. *International Journal of Cancer*, **2008**, 123, 1005-14	7.5	86
375	HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. *Cancer*, **2017**, 123, 4099-4105	6.4	85
374	Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. *Journal of Clinical Oncology*, **2009**, 27, 599-604	2.2	85
373	Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. *Journal of Clinical Oncology*, **2008**, 26, 1879-85	2.2	85
372	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. *Cell Systems*, **2018**, 7, 422-437.e7	10.6	85
371	Molecular epidemiology and retinoid chemoprevention of head and neck cancer. *Journal of the National Cancer Institute*, **1997**, 89, 199-211	9.7	84
370	Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. *Cancer*, **2005**, 104, 561-9	6.4	84
369	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. *Cell Metabolism*, **2017**, 25, 358-373	24.6	83
368	Small-molecule Bax agonists for cancer therapy. *Nature Communications*, **2014**, 5, 4935	17.4	83
367	Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. *Oncology*, **2011**, 81, 12-20	3.6	83
366	Weighing the hazards of erythropoiesis stimulation in patients with cancer. *New England Journal of Medicine*, **2007**, 356, 2445-8	59.2	82
365	Long-term impact of smoking on lung epithelial proliferation in current and former smokers. *Journal of the National Cancer Institute*, **2001**, 93, 1081-8	9.7	82
364	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 128-137	4	80

363	Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. *Journal of Biological Chemistry*, **2010**, 285, 16096-104	5.4	80
362	The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. *Molecular Cancer Therapeutics*, **2007**, 6, 2029-38	6.1	79
361	Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. *Molecular Cell*, **2014**, 55, 552-65	17.6	78
360	Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitorsPanticancer efficacy. *Cancer Biology and Therapy*, **2008**, 7, 1952-8	4.6	78
359	The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. *Cancer Research*, **2008**, 68, 740-8	10.1	78
358	Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. *Seminars in Radiation Oncology*, **2002**, 12, 46-9	5.5	78
357	Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. *Journal of Clinical Oncology*, **2000**, 18, 2798-804	2.2	78
356	Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 16212-6	11.5	77
355	Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. *Clinical Cancer Research*, **2006**, 12, 273-80	12.9	77
354	Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. *Journal of Clinical Oncology*, **2013**, 31, 4179-87	2.2	76
353	Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. *Journal of the National Cancer Institute*, **2003**, 95, 206-14	9.7	75
352	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. *Journal of Thoracic Oncology*, **2019**, 14, 876-889	8.9	74
351	Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. *Cancer Research*, **2005**, 65, 6354-63	10.1	74
350	The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. *Molecular Cell*, **2018**, 69, 87-99.e7	17.6	74
349	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). *Annals of Oncology*, **2015**, 26, 1741-8	10.3	73
348	Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. *Annals of Oncology*, **2004**, 15, 1187-93	10.3	73
347	Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. *JAMA Oncology*, **2017**, 3, 1120-1129	13.4	72
346	The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. *Neoplasia*, **2010**, 12, 346-56	6.4	72

345	2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. *Molecular Cancer Therapeutics*, **2008**, 7, 809-17	6.1	72
344	Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. *Clinical Cancer Research*, **2004**, 10, 2968-76	12.9	72
343	Altered glutamine metabolism and therapeutic opportunities for lung cancer. *Clinical Lung Cancer*, **2014**, 15, 7-15	4.9	71
342	Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. *Cancer Research*, **2005**, 65, 9169-75	10.1	70
341	Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. *Journal of Thoracic Oncology*, **2015**, 10, 462-71	8.9	69
340	Replicative oncolytic adenoviruses in multimodal cancer regimens. *Human Gene Therapy*, **2003**, 14, 933-46	4.8	69
339	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Reports*, **2018**, 23, 172-180.e3	10.6	66
338	Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. *Cancer Research*, **2006**, 66, 11115-9	10.1	66
337	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. *Cancer*, **2016**, 122, 766-72	6.4	65
336	Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. *Clinical Cancer Research*, **2002**, 8, 3796-802	12.9	65
335	Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. *Cancer*, **2001**, 91, 1316-23	6.4	64
334	Correlates of continued smoking versus cessation among survivors of smoking-related cancers. *Psycho-Oncology*, **2013**, 22, 799-806	3.9	62
333	LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. *Cancer Research*, **2008**, 68, 7270-7	10.1	62
332	The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. *PLoS ONE*, **2011**, 6, e20899	3.7	61
331	Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. *Journal of the National Cancer Institute*, **2004**, 96, 1536-48	9.7	61
330	Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. *Oncogene*, **2004**, 23, 6569-80	9.2	61
329	Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. *Journal of Clinical Oncology*, **2002**, 20, 1593-1599	2.2	61
328	Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. *Molecular Cancer Therapeutics*, **2007**, 6, 1317-28	6.1	60

327	Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**,	7.1	60
326	Modernizing Eligibility Criteria for Molecularly Driven Trials. *Journal of Clinical Oncology*, **2015**, 33, 2815-20	20	59
325	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). *Cancer Gene Therapy*, **2000**, 7, 530-6	5.4	59
324	Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. *PLoS ONE*, **2013**, 8, e74670	3.7	59
323	Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. *Cancer Medicine*, **2014**, 3, 1579-94	4.8	58
322	Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. *Nature Communications*, **2013**, 4, 1790	17.4	58
321	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. *Journal of Translational Medicine*, **2016**, 14, 111	8.5	58
320	Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. *Journal of Gastrointestinal Cancer*, **2013**, 44, 143-51	1.6	57
319	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Reports*, **2018**, 23, 213-226	26.63	56
318	Racial disparity in survival of patients with squamous cell carcinoma of the oral cavity and pharynx. *Ethnicity and Health*, **2001**, 6, 165-77	2.2	56
317	Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. *Cancer Research*, **2013**, 73, 5485-96	10.1	54
316	Augmentation of NVP-BEZ235β anticancer activity against human lung cancer cells by blockage of autophagy. *Cancer Biology and Therapy*, **2011**, 12, 549-55	4.6	54
315	Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. *Journal of Clinical Oncology*, **2006**, 24, 4163-9	2.2	54
314	ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. *Journal of Biological Chemistry*, **2010**, 285, 41310-9	5.4	53
313	Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. *Neoplasia*, **2010**, 12, 848-55	6.4	53
312	Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. *Cancer Prevention Research*, **2014**, 7, 283-91	3.2	52
311	Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. *Cancer Prevention Research*, **2009**, 2, 617-24	3.2	52
310	The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. *Blood*, **2005**, 106, 4322-9	2.2	52

309	Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. *Molecular Cancer Therapeutics*, **2014**, 13, 1826-36	6.1	51
308	Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. *Clinical Cancer Research*, **2013**, 19, 1244-56	12.9	50
307	Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect. *Journal of Biological Chemistry*, **2014**, 289, 26533-26541	5.4	50
306	Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). *Cancer Biology and Therapy*, **2006**, 5, 492-7	4.6	50
305	14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. *Blood*, **2007**, 110, 360-9	2.2	50
304	Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer. *Journal of Clinical Oncology*, **2002**, 20, 364-370	2.2	50
303	Adenocarcinoma of the lung in young patients: the M. D. Anderson experience. *Cancer*, **2000**, 88, 1837-41	6.4	50
302	HPV-associated lung cancers: an international pooled analysis. *Carcinogenesis*, **2014**, 35, 1267-75	4.6	49
301	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. *Cancer Letters*, **2012**, 325, 139-46	9.9	49
300	Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. *Cancer Biology and Therapy*, **2012**, 13, 272-80	4.6	49
299	The E3 ubiquitin ligases βTrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. *Molecular Cancer*, **2013**, 12, 146	42.1	48
298	HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?. *Head and Neck Pathology*, **2012**, 6, 336-44	3.3	48
297	Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. *Cancer Prevention Research*, **2009**, 2, 538-45	3.2	48
296	Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. *Clinical Cancer Research*, **2008**, 14, 1581-9	12.9	48
295	PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. *Cancer Biology and Therapy*, **2007**, 6, 99-106	4.6	48
294	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. *Cancer*, **2002**, 95, 322-30	6.4	48
293	Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin. *Oncogene*, **2017**, 36, 254-262	9.2	47
292	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. *Cancer*, **2015**, 121, E1-6	6.4	47

291	Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. *Lung Cancer*, **2012**, 77, 331-8	5.9	47
290	Sex differences in survival in non-small cell lung cancer patients 1974–1998. *Acta Oncologica*, **2004**, 43, 57-64	3.2	47
289	Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. *Journal of Clinical Oncology*, **1999**, 17, 2390-5	2.2	47
288	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. *Clinical Cancer Research*, **2017**, 23, 677-686	12.9	46
287	Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. *Journal of Biological Chemistry*, **2015**, 290, 14120-9	5.4	46
286	Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. *Cell Death and Differentiation*, **2014**, 21, 1160-9	12.7	46
285	The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. *Molecular Cancer Therapeutics*, **2008**, 7, 2212-23	6.1	46
284	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. *Journal of Molecular Diagnostics*, **2016**, 18, 299-315	5.1	45
283	MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. *Carcinogenesis*, **2010**, 31, 2118-23	4.6	45
282	Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. *Clinical Cancer Research*, **2012**, 18, 3705-13	12.9	45
281	Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. *Molecular Cancer Therapeutics*, **2008**, 7, 3556-65	6.1	45
280	c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. *Cancer Biology and Therapy*, **2007**, 6, 1614-20	4.6	45
279	The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. *Journal of Biological Chemistry*, **2007**, 282, 18800-9	5.4	45
278	Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women. A review. *Oncology*, **2004**, 66, 79-93	3.6	45
277	Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. *Clinical Cancer Research*, **2006**, 12, 653-61	12.9	44
276	Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. *Clinical Lung Cancer*, **2016**, 17, e57-e64	4.9	44
275	Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. *Oncogene*, **2016**, 35, 642-50	9.2	43
274	Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. *Journal of Thoracic Oncology*, **2015**, 10, 479-85	8.9	43

273	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. *Cancer Cell*, **2018**, 34, 315-330.e7	24.3	43
272	c-Myc suppression of DNA double-strand break repair. *Neoplasia*, **2012**, 14, 1190-202	6.4	43
271	Fenretinide activity in retinoid-resistant oral leukoplakia. *Clinical Cancer Research*, **2006**, 12, 3109-14	12.9	43
270	Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. *Cancer*, **2001**, 92, 2364-73	6.4	43
269	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. *Molecular Cell*, **2016**, 64, 859-874	17.6	42
268	mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. *Molecular and Cellular Biology*, **2015**, 35, 2344-55	4.8	40
267	NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCδ/FAK loop. *Cancer Letters*, **2012**, 318, 106-13	9.9	40
266	CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non-small-cell lung cancer cells. *Molecular Pharmacology*, **2007**, 72, 1269-79	4.3	40
265	Emerging therapies in non-small-cell lung cancer. *Annals of Oncology*, **2001**, 12, 739-44	10.3	40
264	c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. *PLoS ONE*, **2010**, 5, e10376	3.7	40
263	Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis. *Oral Oncology*, **2015**, 51, 586-92	4.4	39
262	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. *Cancer*, **2014**, 120, 3940-51	6.4	39
261	Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth. *Journal of Biological Chemistry*, **2014**, 289, 21413-22	5.4	39
260	The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. *Journal of Biological Chemistry*, **2013**, 288, 32528-32538	5.4	39
259	Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. *Biochemical Pharmacology*, **2010**, 80, 1309-16	6	39
258	Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. *Journal of Biological Chemistry*, **2013**, 288, 13215-24	5.4	38
257	CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. *Cancer Research*, **2008**, 68, 5335-44	10.1	38
256	Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3. *Oncogene*, **2015**, 34, 2538-45	9.2	37

255	Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase. *Cancer Research*, **2014**, 74, 212-23	10.1	37
254	The care of the lung cancer patient in the 21st century: a new age. *Seminars in Oncology*, **2004**, 31, 11-5	5.5	37
253	Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. *Cancer Research*, **2014**, 74, 2555-68	10.1	36
252	The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. *Molecular Cancer Therapeutics* , **2011**, 10, 2415-25	6.1	36
251	Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. *Molecular Cancer Therapeutics*, **2012**, 11, 45-56	6.1	36
250	Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. *JAMA Otolaryngology*, **2005**, 131, 304-7		36
249	Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. *Cancer Letters*, **2015**, 364, 70-8	9.9	35
248	Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2013**, 8, 369-72	8.9	35
247	Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. *Cancer Prevention Research*, **2009**, 2, 823-9	3.2	35
246	Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. *Journal of Clinical Oncology*, **2009**, 27, 1976-82	2.2	35
245	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. *Cancer*, **2010**, 116, 3903-9	6.4	35
244	New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. *Clinical Cancer Research*, **2005**, 11, 5342-6	12.9	35
243	Chemoprevention of aerodigestive tract cancers. *Annual Review of Medicine*, **2002**, 53, 223-43	17.4	35
242	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. *Clinical Lung Cancer*, **2017**, 18, 286-292	4.9	34
241	Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. *Cancer*, **2015**, 121, 3600-11	6.4	34
240	Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. *Cancer Prevention Research*, **2011**, 4, 185-93	3.2	34
239	Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. *Cancer Research*, **2011**, 71, 5245-54	10.1	34
238	The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. *Oncotarget*, **2015**, 6, 17532-42	3.3	34

237	Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. *JAMA Oncology*, **2015**, 1, 1293-300	13.4	33
236	mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. *Cancer Research*, **2013**, 73, 1946-57	10.1	33
235	Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay. *Journal of Biomolecular Screening*, **2006**, 11, 269-76		33
234	A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. *Cancer*, **2004**, 100, 991-8	6.4	33
233	Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. *PLoS ONE*, **2010**, 5, e12178	3.7	33
232	The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. *Oncotarget*, **2015**, 6, 34669-79	3.3	33
231	Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. *Oncogene*, **2011**, 30, 3802-12	9.2	32
230	A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2009**, 32, 274-9	2.7	32
229	Cables1 complex couples survival signaling to the cell death machinery. *Cancer Research*, **2015**, 75, 147-158	10.1	31
228	Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. *Cancer Prevention Research*, **2014**, 7, 351-61	3.2	31
227	Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. *Cancer Research*, **2011**, 71, 6270-81	10.1	31
226	Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling. *Journal of Biological Chemistry*, **2012**, 287, 257-267	5.4	31
225	Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. *Cancer*, **2016**, 122, 50-60	6.4	30
224	Curcumin induces apoptosis of upper aerodigestive tract cancer cells by targeting multiple pathways. *PLoS ONE*, **2015**, 10, e0124218	3.7	30
223	Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. *Integrative Biology (United Kingdom)*, **2012**, 4, 633-40	3.7	30
222	Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?. *Endocrine-Related Cancer*, **2004**, 11, 191-205	5.7	30
221	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. *Cancer*, **2012**, 118, 164-72	6.4	29
220	Dual engagement of 14-3-3 proteins controls signal relay from ASK2 to the ASK1 signalosome. *Oncogene*, **2010**, 29, 822-30	9.2	29

219	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. *Cancer*, **2002**, 95, 340-53	6.4	29
218	Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. *Journal of the National Cancer Institute*, **1998**, 90, 243-5	9.7	29
217	Targeted therapies in metastatic esophageal cancer: advances over the past decade. *Critical Reviews in Oncology/Hematology*, **2014**, 91, 186-96	7	28
216	The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. *Journal of Biological Chemistry*, **2009**, 284, 9648-55	5.4	28
215	Advances in chemoprevention of head and neck cancer. *Oncologist*, **2004**, 9, 302-11	5.7	28
214	Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. *Seminars in Oncology*, **2002**, 29, 15-26	5.5	28
213	Molecularly targeted approaches to the chemoprevention of lung cancer. *Clinical Cancer Research*, **2004**, 10, 4249s-4253s	12.9	28
212	Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. *Supportive Care in Cancer*, **2016**, 24, 1789-93	3.9	27
211	Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. *Head and Neck*, **2013**, 35, 443-53	4.2	27
210	Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. *Oncologist*, **2013**, 18, 600-10	5.7	27
209	c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. *Molecular Cancer*, **2010**, 9, 315	42.1	27
208	Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. *Seminars in Oncology*, **2004**, 31, 809-15	5.5	27
207	PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).. *Journal of Clinical Oncology*, **2010**, 28, 7596-7596	2.2	27
206	Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck. *Head and Neck Pathology*, **2014**, 8, 66-72	3.3	26
205	Farnesyltransferase inhibitors reverse taxane resistance. *Cancer Research*, **2006**, 66, 8838-46	10.1	26
204	The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. *Cancer Biology and Therapy*, **2004**, 3, 1092-8; discussion 1099-1101	4.6	26
203	The OncoPPi Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery. *Bioinformatics*, **2018**, 34, 1183-1191	7.2	25
202	The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. *Cancer Letters*, **2013**, 338, 229-38	9.9	25

201	Integration of apoptosis signal-regulating kinase 1-mediated stress signaling with the Akt/protein kinase B-IB kinase cascade. *Molecular and Cellular Biology*, **2013**, 33, 2252-9	4.8	24
200	Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. *Nanotechnology*, **2009**, 20, 225102	3.4	24
199	Communicating suffering in primary stage head and neck cancer. *European Journal of Cancer Care*, **2004**, 13, 53-64	2.4	24
198	Chemoprevention of lung cancer. *Current Opinion in Pulmonary Medicine*, **2004**, 10, 279-83	3	24
197	Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. *Oncotarget*, **2015**, 6, 41324-38	3.3	24
196	Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. *Cancer*, **2014**, 120, 1394-400	6.4	23
195	Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. *Southern Medical Journal*, **2003**, 96, 1031-3	0.6	23
194	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. *Journal of Thoracic Oncology*, **2021**, 16, 464-476	8.9	23
193	Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax. *PLoS ONE*, **2010**, 5, e13393	3.7	22
192	Comparison and optimization of multiplexed quantum dot-based immunohistofluorescence. *Nano Research*, **2010**, 3, 61-68	10	22
191	Lung cancer chemoprevention. *Journal of Surgical Oncology*, **2000**, 18, 100-5		22
190	Patterns of extralaryngeal spread of laryngeal cancer: thyroid cartilage penetration occurs in a minority of patients with extralaryngeal spread of laryngeal squamous cell cancers. *Cancer*, **2011**, 117, 5047-51	6.4	21
189	Targeting adhesion signaling in mutant lung adenocarcinoma. *JCI Insight*, **2017**, 2, e90487	9.9	21
188	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 1859-68	12.9	20
187	CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. *Clinical Cancer Research*, **2013**, 19, 1603-11	12.9	20
186	p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms. *Molecular and Cellular Biology*, **2013**, 33, 2574-85	4.8	20
185	A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. *British Journal of Cancer*, **2013**, 108, 762-5	8.7	20
184	Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. *Carcinogenesis*, **2010**, 31, 1755-61	4.6	20

183	Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond. *Cell Cycle*, **2011**, 10, 3274-83	4.7	20
182	Head and neck cancer chemoprevention gets a shot in the arm. *Journal of Clinical Oncology*, **2008**, 26, 345-7	2.2	20
181	A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 717-24	4	20
180	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).. *Journal of Clinical Oncology*, **2012**, 30, 5501-5501	2.2	20
179	A qualitative study of head and neck cancer. *Supportive Care in Cancer*, **2004**, 12, 338-46	3.9	19
178	Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. *Journal of the National Cancer Institute*, **2003**, 95, 165-8	9.7	19
177	A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.. *Journal of Clinical Oncology*, **2011**, 29, 5502-5502	2.2	19
176	HMG-CoA synthase 1 is a synthetic lethal partner of BRAF in human cancers. *Journal of Biological Chemistry*, **2017**, 292, 10142-10152	5.4	18
175	Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform. *Journal of Molecular Cell Biology*, **2016**, 8, 271-81	6.3	18
174	A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors. *Assay and Drug Development Technologies*, **2013**, 11, 367-81	2.1	18
173	Chemoprevention of squamous cell carcinoma of the head and neck. *Current Opinion in Oncology*, **2007**, 19, 180-7	4.2	18
172	A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. *Radiotherapy and Oncology*, **2002**, 63, 187-93	5.3	18
171	AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay. *Molecular Pharmacology*, **2017**, 91, 339-347	4.3	17
170	OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. *Oncogene*, **2017**, 36, 5852-5860	9.2	17
169	Modulation of Bax and mTOR for Cancer Therapeutics. *Cancer Research*, **2017**, 77, 3001-3012	10.1	17
168	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. *Apoptosis: an International Journal on Programmed Cell Death*, **2015**, 20, 986-95	5.4	17
167	The first Surgeon GeneralÃ¢ report on smoking and health: the 50th anniversary. *Ca-A Cancer Journal for Clinicians*, **2014**, 64, 5-8	220.7	17
166	Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. *Molecular Cancer*, **2010**, 9, 23	42.1	17

165	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, e395-e401	7.1	17
164	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. *Lung Cancer*, **2015**, 88, 80-4	5.9	16
163	Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. *Journal of Thoracic Oncology*, **2015**, 10, 1142-7	8.9	16
162	Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. *Cancer Research*, **2005**, 65, 5841-7	10.1	16
161	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. *Oral Oncology*, **2014**, 50, 888-94	4.4	15
160	GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. *Oncotarget*, **2015**, 6, 8974-87	3.3	15
159	Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma. *Cancer Biology and Therapy*, **2013**, 14, 365-9	4.6	15
158	Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. *Journal of the National Cancer Institute*, **2007**, 99, 1603-12	9.7	15
157	Targeting mTOR Signaling for Lung Cancer Therapy. *Journal of Thoracic Oncology*, **2006**, 1, 109-111	8.9	15
156	RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. *Oncogene*, **2016**, 35, 5412-5421	9.2	15
155	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. *Head and Neck*, **2019**, 41, 1490-1498	4.2	14
154	Transcriptional regulation of YWHAZ, the gene encoding 14-3-3 *PLoS ONE*, **2014**, 9, e93480	3.7	14
153	Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. *Cancer*, **2011**, 117, 4049-59	6.4	14
152	The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. *Cancer Research*, **2007**, 67, 4973-80	10.1	14
151	O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). *Lung Cancer*, **2005**, 49, S30	5.9	14
150	Progress in lung cancer chemoprevention. *Cancer Control*, **2003**, 10, 315-24	2.2	14
149	Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. *Contemporary Clinical Trials*, **2015**, 43, 133-41	2.3	13
148	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. *Therapeutic Advances in Medical Oncology*, **2015**, 7, 56-62	5.4	13

147	Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. *Molecular Cancer Therapeutics*, **2009**, 8, 2575-85	6.1	13
146	Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis. *Head and Neck*, **2009**, 31, 1447-55	4.2	13
145	Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. *Journal of Receptor and Signal Transduction Research*, **2009**, 29, 182-94	2.6	13
144	Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. *Clinical Cancer Research*, **2005**, 11, 4151-9	12.9	13
143	ZD1839 (Iressa) in non-small-cell lung cancer. *Clinical Lung Cancer*, **2001**, 3, 27-32	4.9	13
142	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study **2020**, 8,		13
141	A homogenous luminescent proximity assay for 14-3-3 interactions with both phosphorylated and nonphosphorylated client peptides. *Current Chemical Genomics*, **2008**, 2, 40-7		13
140	Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. *Oncology*, **2006**, 20, 153-61; discussion 162, 166, 169 passim	1.8	13
139	The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. *Oncologist*, **2009**, 14, 412-24	5.7	12
138	Novel agents and incremental advances in the treatment of head and neck cancer. *Seminars in Oncology*, **2004**, 31, 3-10	5.5	12
137	Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. *Clinical Lung Cancer*, **2003**, 5 Suppl 1, S36-40	4.9	12
136	The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses. *Oncology*, **2005**, 68, 18-22	3.6	12
135	A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).. *Journal of Clinical Oncology*, **2013**, 31, CRA8007-CRA8007	2.2	12
134	Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. *Oncogene*, **2016**, 35, 459-67	9.2	11
133	Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2017**, 18, e203-e210	4.9	11
132	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. *Clinical Lung Cancer*, **2019**, 20, 484-493.e6	4.9	11
131	FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. *Cancer Letters*, **2015**, 363, 166-75	9.9	11
130	Laryngeal tumor volume as a predictor for thyroid cartilage penetration. *Head and Neck*, **2013**, 35, 426-30	4.2	11

129	Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. *Cancer*, **2013**, 119, 1503-11	6.4	11
128	The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition. *Cancer Prevention Research*, **2012**, 5, 612-20	3.2	11
127	Prevention of head and neck cancer: current status and future prospects. *Current Problems in Cancer*, **2004**, 28, 265-86	2.3	11
126	Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.. *Journal of Clinical Oncology* , **2017**, 35, 9021-9021	2.2	11
125	Gene methylation biomarkers in sputum as a classifier for lung cancer risk. *Oncotarget*, **2017**, 8, 63978-63985	3.3	11
124	Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts. *Current Cancer Drug Targets*, **2014**, 14, 380-93	2.8	11
123	Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. *Cancer Medicine*, **2020**, 9, 8406-8411	4.8	11
122	Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy. *Head and Neck*, **2016**, 38, 846-51	4.2	11
121	Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. *Cancer Prevention Research*, **2017**, 10, 635-640	3.2	10
120	Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC. *PLoS ONE*, **2014**, 9, e107124	3.7	10
119	Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. *Journal of Clinical Pharmacy and Therapeutics*, **2006**, 31, 401-6	2.2	10
118	Retinoids in lung cancer: friend, foe, or fellow traveler?. *Journal of Clinical Oncology*, **2004**, 22, 3435-7	2.2	10
117	Chemoprevention strategies for patients with lung cancer in the context of screening. *Clinical Lung Cancer*, **2005**, 7, 92-9	4.9	10
116	Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs. *Oncotarget*, **2014**, 5, 3197-209	3.3	10
115	Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance. *Molecular Cancer Research*, **2016**, 14, 675-82	6.6	9
114	Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials. *Contemporary Clinical Trials*, **2014**, 37, 322-32	2.3	9
113	Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. *Oncologist*, **2013**, 18, 1262-9	5.7	9
112	Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data. *BioMedical Engineering OnLine*, **2011**, 10, 97	4.1	9

111	Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. *Current Opinion in Oncology*, **2009**, 21, 232-7	4.2	9
110	Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck. *Head and Neck*, **2007**, 29, 351-61	4.2	9
109	Targeting angiogenesis in head and neck cancer. *Current Cancer Drug Targets*, **2007**, 7, 643-9	2.8	9
108	Chemoprevention of lung cancer: current status and future prospects. *Cancer and Metastasis Reviews*, **2002**, 21, 349-62	9.6	9
107	WaldenstrÃ¶m macroglobulinemia with an IgM paraprotein that is both a cold agglutinin and a cryoglobulin and has a suppressive effect on progenitor cell growth. *Transfusion*, **1994**, 34, 910-4	2.9	9
106	Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. *Oncoscience*, **2015**, 2, 765-776	0.8	9
105	Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. *Oncotarget*, **2015**, 6, 30773-86	3.3	9
104	Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression. *Lung Cancer*, **2015**, 88, 131-8	5.9	8
103	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. *Molecular Cell*, **2018**, 69, 923-937.e8	17.6	8
102	Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. *Cancer Biology and Therapy*, **2007**, 6, 749-54	4.6	8
101	Update in the management of head and neck cancer. *Update on Cancer Therapeutics*, **2006**, 1, 211-219		8
100	Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. *Oncologist*, **2020**, 25, e964-e975	5.7	7
99	Second-generation ALK inhibitors: filling the non "MET" gap. *Cancer Discovery*, **2014**, 4, 634-6	24.4	7
98	A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). *Journal of Clinical Oncology*, **2005**, 23, 5565-5565	2.2	7
97	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. *Oncotarget*, **2017**, 8, 59008-59022	3.3	7
96	Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 148-52	2.7	7
95	Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. *Cancer Prevention Research*, **2016**, 9, 63-73	3.2	6
94	Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. *Lung Cancer*, **2018**, 123, 36-43	5.9	6

93	Chemoprevention of respiratory tract cancer. *Hematology/Oncology Clinics of North America*, **1997**, 11, 387-408	3.1	6
92	Targeting mTOR Signaling for Lung Cancer Therapy. *Journal of Thoracic Oncology*, **2006**, 1, 109-111	8.9	6
91	Chemoprevention of lung cancer. *Current Oncology Reports*, **2002**, 4, 341-6	6.3	6
90	Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. *Journal of Interferon and Cytokine Research*, **1998**, 18, 241-5	3.5	6
89	LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions. *Oncotarget*, **2016**, 7, 2519-31	3.3	6
88	Targeting mTOR signaling for lung cancer therapy. *Journal of Thoracic Oncology*, **2006**, 1, 109-11	8.9	6
87	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. *PLoS ONE*, **2019**, 14, e0206309	3.7	5
86	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. *Clinical Cancer Research*, **2020**, 26, 2497-2505	12.9	5
85	Pain Intensity and Pain Interference in Patients With Lung Cancer: A Pilot Study of Biopsychosocial Predictors. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2015**, 38, 457-64	2.7	5
84	Prevention of Lung Cancer: Future Perspective with Natural Compounds. *Tuberculosis and Respiratory Diseases*, **2010**, 69, 1	3.2	5
83	The dawn of a revolution in personalized lung cancer prevention. *Cancer Prevention Research*, **2011**, 4, 949-53	3.2	5
82	The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. *Oncology*, **2005**, 68, 10-7	3.6	5
81	Taxanes in the treatment of non-small cell lung cancer. *Treatments in Respiratory Medicine*, **2006**, 5, 181-91		5
80	Recent advances in the management of squamous cell carcinoma of the head and neck. *Expert Review of Anticancer Therapy*, **2001**, 1, 99-110	3.5	5
79	A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).. *Journal of Clinical Oncology*, **2019**, 37, 8515-8515	2.2	5
78	Development and testing of a tool to assess patient preferences for phase I clinical trial participation. *Psycho-Oncology*, **2015**, 24, 835-8	3.9	4
77	Moving toward bioadjuvant approaches to head and neck cancer prevention. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S132-5	4	4
76	Chemoprevention of lung cancer: concepts and strategies. *Expert Review of Anticancer Therapy*, **2005**, 5, 549-65	3.5	4

75	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. *Clinical Cancer Research*, **2020**, 26, 5860-5868	12.9	4
74	1187 Molecular Mechanism of Synergistic Anti-tumor Activity by the Combination of Natural Compounds Green Tea (-)Epigallocathetin-3-gallate (EGCG) and Resveratrol for Potential Chemoprevention in Head and Neck Cancer (HNC). *European Journal of Cancer*, **2012**, 48, S286	7.5	3
73	What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. *Therapeutic Advances in Medical Oncology*, **2010**, 2, 229-35	5.4	3
72	Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2009**, 32, 15-9	2.7	3
71	Emerging drugs for head and neck cancer. *Expert Opinion on Emerging Drugs*, **2004**, 9, 91-104	3.7	3
70	Chemoprevention in lung cancer. *Current Problems in Cancer*, **2004**, 28, 287-306	2.3	3
69	Antitumor effects of combined bortezomib and tipifarnib in head and neck squamous cell carcinoma (HNSCC) cells. *Journal of Clinical Oncology*, **2006**, 24, 5581-5581	2.2	3
68	Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.. *Journal of Clinical Oncology*, **2011**, 29, 7553-7553	2.2	3
67	MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development. *PLoS ONE*, **2017**, 12, e0170339	3.7	3
66	Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS TM)" for Cancer Phase I Clinical Trials. *Open Medical Informatics Journal*, **2013**, 7, 8-17	1	3
65	Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. *Journal of Thoracic Disease*, **2019**, 11, 2383-2391	2.6	2
64	Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables. *Clinical Lung Cancer*, **2013**, 14, 128-38	4.9	2
63	Energizing the search to target LKB1-mutant tumors. *Cancer Discovery*, **2013**, 3, 843-5	24.4	2
62	1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies. *European Journal of Cancer*, **2011**, 47, S153	7.5	2
61	Can statins pass the aspirin litmus test in cancer?. *Journal of Clinical Oncology*, **2007**, 25, 3395-6	2.2	2
60	Novel targeted agents in the treatment of lung cancer. *Expert Opinion on Investigational Drugs*, **2004**, 13, 609-29	5.9	2
59	Abstract 1460: Quantification of circulating tumor cells using multiplexed Surface-Enhanced Raman Scattering Nanoparticles. **2013**,		2
58	Definitive treatment of intermediate stage laryngeal squamous cell (SCC/L) cancer with chemotherapy (CT). *Journal of Clinical Oncology*, **2004**, 22, 5533-5533	2.2	2

57	Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study.. *Journal of Clinical Oncology*, **2010**, 28, 5535-5535	2.2	2
56	Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.. *Journal of Clinical Oncology*, **2011**, 29, e13601-e13601	2.2	2
55	In Lebanon "It Never Rains But It Pours"-How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises. *FASEB BioAdvances*, **2021**, 3, 676-682	2.8	2
54	The Beirut Port explosion: injury trends from a mass survey of emergency admissions. *Lancet, The*, **2021**, 398, 21-22	40	2
53	Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. *Oncology*, **2002**, 16, 53-62	1.8	2
52	Business as usual is not acceptable. *Cancer*, **2015**, 121, 2864-5	6.4	1
51	New Directions in Lung Cancer: Chemoprevention. *Seminars in Respiratory and Critical Care Medicine* , **1996**, 17, 323-334	3.9	1
50	Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion. *Cancer Research* , **2008**, 68, 4013-4017	10.1	1
49	Farnesyltransferase inhibitors: a promising future in cancer treatment. *Clinical Lung Cancer*, **2002**, 4, 63-4	4.9	1
48	A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.. *Journal of Clinical Oncology*, **2012**, 30, 2576-2576	2.2	1
47	Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC).. *Journal of Clinical Oncology*, **2014**, 32, 6068-6068	2.2	1
46	Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis.. *Journal of Clinical Oncology*, **2014**, 32, 6085-6085	2.2	1
45	Second primary lung cancers: Analysis of E5597 selenium chemoprevention study.. *Journal of Clinical Oncology*, **2014**, 32, 7518-7518	2.2	1
44	Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A Surveillance, Epidemiology, and End Results database analysis.. *Journal of Clinical Oncology*, **2014**, 32, 7554-7554	2.2	1
43	Concurrent chemoradiation using weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis.. *Journal of Clinical Oncology*, **2015**, 33, 6055-6055	2.2	1
42	Dual targeting of EGFR and HER3 with cetuximab and MM-121/SAR256212 in HNSCC patient derived xenograft (PDX) models.. *Journal of Clinical Oncology*, **2015**, 33, e17066-e17066	2.2	1
41	Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, 9035-9035	2.2	1
40	HER2 mutations in lung adenocarcinoma: A report from the Lung Cancer Mutation Consortium (LCMC).. *Journal of Clinical Oncology*, **2014**, 32, 8060-8060	2.2	1

39	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. *British Journal of Cancer*, **2020**, 123, 1228-1234	8.7	1
38	Lung203-220		1
37	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. *Cancers*, **2022**, 14, 2639	6.6	1
36	Locally advanced lung cancer. *Ca-A Cancer Journal for Clinicians*, **2021**, 71, 461-465	220.7	0
35	A better angel of our nature: Hanna Michel "Jean" Khoury, MD (April 24, 1967-May 22, 2017). *Cancer*, **2017**, 123, 2998-3002	6.4	
34	Cytotoxic Chemotherapy **2017**, 220-235		
33	AACR celebrates 50 years of tobacco research and policy. *Clinical Cancer Research*, **2014**, 20, 1709-18	12.9	
32	Of Gdansk and glass houses. *Cancer*, **2014**, 120, 612-3	6.4	
31	Laryngeal squamous cell carcinoma metastatic to a flank intramuscular lipoma. *American Surgeon*, **2008**, 74, 447-448	0.8	
30	Erythropoietins in oncology. *New England Journal of Medicine*, **2007**, 357, 1262; author reply 1262-3	59.2	
29	Prevention and Early Detection of Lung Cancer **2003**, 256-279		
28	Chemoprevention of Lung Cancer **2006**, 609-626		
27	Chemoprevention of Upper Aerodigestive Tract Cancer **2005**, 371-382		
26	Chemoprevention in Head and Neck Cancer **2005**, 279-303		
25	Aerodigestive Tract Chemoprevention Trials and Prevention of Second Primary Tumors **2003**, 271-285		
24	Concurrent platinum-based chemotherapy with intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): A retrospective single institution analysis. *Journal of Clinical Oncology*, **2007**, 25, 16511-16511	2.2	
23	Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.. *Journal of Clinical Oncology*, **2019**, 37, 6049-6049	2.2	
22	Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.. *Journal of Clinical Oncology*, **2014**, 32, 2589-2589	2.2	

21	Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions.. *Journal of Clinical Oncology*, **2014**, 32, 9646-9646	2.2
20	Predictive value of gene expression signatures in premalignant lesions of the head and neck for response to chemoprevention with EGFR and COX-2 inhibitors.. *Journal of Clinical Oncology*, **2014**, 32, e17053-e17053	2.2
19	Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy.. *Journal of Clinical Oncology*, **2014**, 32, 7599-7599	2.2
18	Standardizing measurement of tobacco use in cancer clinical trials.. *Journal of Clinical Oncology*, **2014**, 32, e17658-e17658	2.2
17	Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis.. *Journal of Clinical Oncology*, **2014**, 32, e17632-e17632	2.2
16	Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data.. *Journal of Clinical Oncology*, **2015**, 33, 6073-6073	2.2
15	Necitumumab in metastatic squamous non-small cell lung cancer (mSqNSCLC): Establishing a value-based cost.. *Journal of Clinical Oncology*, **2015**, 33, 6505-6505	2.2
14	Lung203-220	
13	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers **2016**, 555-567	
12	National Cancer Data Base analysis of proton versus photon radiotherapy in non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2016**, 34, 8501-8501	2.2
11	Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).. *Journal of Clinical Oncology*, **2016**, 34, e20022-e20022	2.2
10	Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.. *Journal of Clinical Oncology*, **2017**, 35, 8565-8565	2.2
9	Early proliferation of PD-1+ CD8 T cells in peripheral blood as predictive of response to PD-1 inhibition for patients with advanced NSCLC.. *Journal of Clinical Oncology*, **2017**, 35, e20648-e20648	2.2
8	Optimal thoracic radiation dose in limited stage small cell lung cancer.. *Journal of Clinical Oncology*, **2017**, 35, 8562-8562	2.2
7	caGrid-Enabled caBIG Silver Level Compatible Head and Neck Cancer Tissue Database System. *Open Medical Informatics Journal*, **2010**, 4, 171-8	1
6	Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth. *Blood*, **2010**, 116, 3142-3142	2.2
5	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers **2011**, 471-481	
4	Screening of novel small molecule inhibitors of NF-B activation in lung cancer. *FASEB Journal*, **2013** , 27, lb581	0.9

3	EditorB Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*, **2019**, 25, 4861	12.9
2	Where it all began. *Cancer*, **2021**, 127, 4541-4545	6.4
1	Retinoids and Rexinoids in Lung Cancer Prevention and Treatment386-399	